Matthew B. Klein is the Chief Executive Officer at PTC Therapeutics Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for rare disorders. With a robust background in the biopharmaceutical industry, Klein has been instrumental in steering PTC Therapeutics towards its mission of providing life-changing therapies to patients with unmet medical needs. Prior to joining PTC, Klein held various leadership positions at other notable biotech firms, where he honed his skills in strategic planning, drug development, and corporate management. At PTC Therapeutics, Klein has been pivotal in advancing the company's pipeline and expanding its global reach. Under his leadership, PTC has successfully launched several groundbreaking treatments, notably including Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). Klein's strategic vision has also led to the development of a diverse portfolio of therapeutic candidates targeting various rare diseases. His commitment to innovation and patient-centric approaches has earned him recognition within the industry and among patient advocacy groups. In addition to his role at PTC Therapeutics, Klein is actively involved in the broader biopharmaceutical community, often speaking at industry conferences and contributing to discussions on the future of rare disease treatments. His leadership style emphasizes collaboration, scientific excellence, and a relentless focus on improving patient outcomes. Klein's dedication to advancing the field of rare disease therapeutics continues to drive PTC Therapeutics forward as a leader in the industry.